Abdelmalek M, Choi J, Kim Y et al (2020) HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: a Phase 1b/2a, multi-center, randomized, placebo-controlled trial. J Hepatol 73:S124.
ADLYXIN (lixisenatide) injection [prescribing information]. Accessed 27 Dec 2023
ADMELOG™ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION by Sanofi-aventis Canada Inc. Accessed 27 Dec 2023
Adrian TE, Ferri GL, Bacarese-Hamilton AJ et al (1985) Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89:1070–1077.
AFREZZA® (insulin human) Inhalation Powder for oral inhalation [prescribing information]. Accessed 27 Dec 2023
Ahn J-M, Kassees K, Lee T-K et al (2017) 6.03—strategy and tactics for designing analogs: biochemical characterization of the large molecules☆. In: Chackalamannil S, Rotella D, Ward SEBT-CMCIII (eds) Elsevier, Oxford, pp 66–115
Ahrén B, Hedner P, Lundquist I (1983) Interaction of gastric inhibitory polypeptide (GIP) and cholecystokinin (CCK-8) with basal and stimulated insulin secretion in mice. Acta Endocrinol (copenh) 102:96–102.
Ahrén B, Holst JJ, Efendic S (2000) Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes*. J Clin Endocrinol Metab 85:1043–1048.
Åkesson B, Panagiotidis G, Westermark P, Lundquist I (2003) Islet amyloid polypeptide inhibits glucagon release and exerts a dual action on insulin release from isolated islets. Regul Pept 111:55–60.
Alarcon C, Lincoln B, Rhodes CJ (1993) The biosynthesis of the subtilisin-related proprotein convertase PC3, but not that of the PC2 convertase, is regulated by glucose in parallel to proinsulin biosynthesis in rat pancreatic islets. J Biol Chem 268:4276–4280.
Aldawsari M, Almadani FA, Almuhammadi N et al (2023) The Efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: systematic review of randomized controlled trials. Diabetes Metab Syndr Obes 16:575–595.
Ali R, Virendra SA, Chawla PA (2022) Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist. Heal Sci Rev 4:100032.
American Diabetes Association (2009) Diagnosis and classification of diabetes mellitus. Diabetes Care 32(Suppl 1):S62–S67.
APIDRA® (insulin glulisine [rDNA origin] injection) solution for injection [prescribing information]. Accessed 27 Dec 2023
Atkinson MA, Eisenbarth GS (2001) Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet (london, England) 358:221–229.
Bækdal TA, Donsmark M, Hartoft-Nielsen ML et al (2021) Relationship between oral semaglutide tablet erosion and pharmacokinetics: a pharmacoscintigraphic study. Clin Pharmacol Drug Dev 10:453–462.
Baggio LL, Drucker DJ (2007a) Biology of Incretins: GLP-1 and GIP. Gastroenterology 132:2131–2157.
Baggio LL, Drucker DJ (2007b) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131–2157.
Banday MZ, Sameer AS, Nissar S (2020) Pathophysiology of diabetes: an overview. Avicenna J Med 10:174–188.
Bansal P, Wang Q (2008) Insulin as a physiological modulator of glucagon secretion. Am J Physiol Endocrinol Metab.
Barnett AH (2012) The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide. Diabetes Obes Metab 14:304–314.
Barrington P, Chien JY, Showalter HDH et al (2011) A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab 13:426–433.
